Protuupalno i analgetsko djelovanje ekstrakta cijele biljke Fumaria indica na eksperimentalnim životinjama

The 50% ethanolic extract of Fumaria indica was investigated for its anti-inflammatory and antinociceptive potential in animal models. Oral administration of F. indica dry extract (100, 200 and 400 mg kg1) exhibited dose dependent and significant anti-inflammatory activity in acute (carrageenean and histamine induced hind paw oedema – p < 0.05) and chronic (cotton pellet granuloma models of inflammation – p < 0.01). The extract (400 mg kg1) exhibited maximum anti-inflammatory effects of 42.2 and 42.1% after 3 h with carrageenean and histamine respectively. The same dose of extract showed 38.9% reduction in granuloma mass in a chronic condition. A significant anti-nociceptive activity was evidenced in mice; 6.6–67.7% (p < 0.01) protection in mechanical, 33.9–125.1% (p < 0.05) protection in thermal induced pain and 22.2–73.9% (p < 0.05) protection in acetic acid-induced writhing.Na animalnom modelu ispitivano je protuupalno i analgetsko djelovanje ekstrakta biljke Fumaria indica sa 50%-tnim etanolnom. Peroralna primjena suhog ekstrakta F. indica (100, 200 i 400 mg kg1) pokazuje značajno i o dozi ovisno protuupalno djelovanje na akutni (edem šape uzrokovan karagenom i histaminom – p < 0.05) i kronični upalni proces (granulomi uzrokovani pamučnim peletama – p < 0.01). Najveći protuupalni učinak u karagenskom, odnosno histaminskom testu od 42,2 i 42,1% dobiven je s dozom 400 mg kg1 nakon 3 h. Ista doza ekstrakta pokazala je 38,9% smanjenje mase granuloma. Značajno analgetsko djelovanje dokazano je pokusima na miševima: 6,6–67,7% (p < 0,01) zaštita od mehanički izazvane boli, 33,9–125,1% (p < 0,05) zaštita od termički izazvane boli i 22,2–73,9% (p < 0,05) zaštita od kemijski izazvane boli octenom kiselinom

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all &gt;0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

Sweet sorghum R&amp;D at the Nimbkar Agricultural Research Institute (NARI)

The research work on sweet sorghum carried out at the Nimbkar Agricultural Research Institute (NARI) during last twenty-five years has been summarized. American lines were crossed with a local Indian fodder/grain variety to produce varieties with a juicy stalk and good quality grain. Further breeding was carried out to produce varieties and hybrids giving high yield of good quality grain while retaining the characteristic of juicy stalks high in sugar. Complete development of indigenous technology for fermentation of sweet sorghum juice, solar distillation of ethanol and finally its use as a cooking and lighting fuel in new and improved stoves and lanterns was carried out. The technology of producing jaggery (unrefined sugar) and syrup from sweet sorghum was also developed. Consumer response to these products was assessed by marketing them in limited quantities. A completely automated multifuel gasification system capable of producing thermal output between 120-500 kW was developed for direct heat applications such as those in jaggery and syrup making units. Sweet sorghum bagasse was also tested in an existing paper mill to assess its suitability for paper manufacture. Areas of possible research for better exploitation of sweet sorghum have been suggested

Syrup Production from Sweet Sorghum

This paper presents pioneering developmental work on syrup production from sweet sorghum. A hybrid sweet sorghum ‘Madhura ’ has been developed which produces excellent syrup. This paper details the agronomy and the juice characteristics of this hybrid. Protocols for making excellent syrup from sweet sorghum are also outlined. Finally an economic analysis for syrup production is detailed. Sweet sorghum-an attractive feedstock for syrup making Sweet sorghum [Sorghum bicolor (L.) Moench] is the best multipurpose crop for simultaneous production of (i) grain from its earhead as food, (ii) sugary juice from its stalk for making syrup, jaggery or ethanol and (iii) bagasse and green foliage as an excellent fodder for animals, as biomass for gasification system, as organic fertilizer or for paper manufacturing. Moreover, sweet sorghum has a great tolerance to a wide range of climatic and soil conditions. It is a short duration crop of 110-130 days as compared to 12-18 months in sugarcane. In addition its water and fertilizer requirement is much less, resulting in lower cost of cultivation than sugarcane. Sweet sorghum is a plant with C4 photosyntheti

Expression of the FecB Gene in Garole and crossbred ewes in Maharashtra, India

Obulation rate (OR) and litter size (LS) records from 227 1/4 Garole ewes genotyped for 'FecB' were analysed. Roughtly half of the 1/4 Garole ewes were heterozygotes ('FecB'^B+) and half were non-carriers ('FecB'^++). One copy of 'FecB' increased OR from 1.03 to 2.02 and LS from 1.01 to 1.83 (average of second and third parities) in multiparous ewes. The other breeds and crosses studied were largely confounded with 'FecB' genotype. However, the results were similar when records of ewes of different genetic backgrounds, i.e. non-carrier Deccani and Bannur ewes and heterozygote Garole and F1 ewes, were added to the analysis. The increase in prolificacy caused by the introduction of the 'FecB' gene into a non-prolific breed such as the Deccani is likely to produce a useful outcome with a manageable range of litter sizes in flocks carrying the gene

Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing

BackgroundA paucity of data exists regarding inherited mutations associated with phyllodes tumors (PT); however, some are reported (TP53, BRCA1, and RB1). A PT diagnosis does not meet NCCN criteria for testing, including within Li-Fraumeni Syndrome (TP53). We sought to determine the prevalence of mutations associated with PT.MethodsWe performed an 11-institution review of contemporary (2007-2017) PT practice. We recorded multigenerational family history and personal history of genetic testing. We identified patients meeting NCCN criteria for genetic evaluation. Logistic regression estimated the association of select covariates with likelihood of undergoing genetic testing.ResultsOf 550 PT patients, 59.8% (n = 329) had a close family history of cancer, and 34.0% (n = 112) had ≥ 3 family members affected. Only 6.2% (n = 34) underwent genetic testing, 38.2% (n = 13) of whom had only BRCA1/BRCA2 tested. Of 34 patients tested, 8.8% had a deleterious mutation (1 BRCA1, 2 TP53), and 5.9% had a BRCA2 VUS. Of women who had TP53 testing (N = 21), 9.5% had a mutation. Selection for testing was not associated with age (odds ratio [OR] 1.01, p = 0.55) or PT size (p = 0.12) but was associated with grade (malignant vs. benign: OR 9.17, 95% CI 3.97-21.18) and meeting NCCN criteria (OR 3.43, 95% confidence interval 1.70-6.94). Notably, an additional 86 (15.6%) patients met NCCN criteria but had no genetic testing.ConclusionsVery few women with PT undergo germline testing; however, in those selected for testing, a deleterious mutation was identified in ~ 10%. Multigene testing of a PT cohort would present an opportunity to discover the true incidence of germline mutations in PT patients

Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines.

PurposePhyllodes tumors (PTs) are rare breast neoplasms, which have little granular data on margins. Current guidelines recommend ≥ 1 cm margins; however, recent data suggest narrower margins are sufficient, and for benign PT, a negative margin may not be necessary.MethodsWe performed an 11-institution contemporary (2007-2017) review of PT practices. Demographics, surgical, and histopathologic data were captured. Logistic regression was used to estimate the association of select covariates with local recurrence (LR).ResultsOf 550 PT patients, the majority underwent excisional biopsy (55.3%, n = 302/546) or lumpectomy (wide excision) (38.5%, n = 210/546). Median tumor size was 30 mm, 68.9% (n = 379) were benign, 19.6% (n = 108) borderline, and 10.5% (n = 58) malignant. Surgical margins were positive in 42% (n = 231) and negative in 57.3% (n = 311). A second operation was performed in 38.0% (n = 209) of the total cohort, including 51 patients with an initial negative margin (82.4% with &lt; 2 mm), and 157 with an initial positive margin, with residual disease only found in six (2.9%). Notably, 32.0% (n = 74) of those with an initial positive margin did not undergo a second operation, among whom only 2.7% (n = 2) recurred. Recurrence occurred in 3.3% (n = 18) of the total cohort (n = 15 LR, n = 3 distant), at median follow-up of 36.7 months. LR (all PT grades) was not reduced with wider negative margin width (≥ 2 mm v &lt; 2 mm: odds ratio [OR] = 0.39; 95% CI, 0.07 to 2.10; P = .27) or final margin status (positive v negative: OR = 0.96; 95% CI, 0.26 to 3.52; P = .96).ConclusionIn current practice, many patients are managed outside of current guidelines. For the entire cohort, a wider margin width was not associated with a reduced risk of LR. We do not recommend re-excision of a negative margin for benign PT, regardless of margin width, as a progressively wider surgical margin is unlikely to reduce LR